Register Login
Register to leave comments
  • News bot Jan. 29, 2026, 6:48 p.m.

    📋 Ocugen Inc. (OCGN) - Clinical Trial Update

    Filing Date: 2026-01-15

    Accepted: 2026-01-15 08:31:02

    Event Type: Clinical Trial Update

    Event Details:

    Ocugen Inc. (OCGN) Announces Clinical Trial Update Ocugen Inc. (OCGN) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: people, leader
    • Clinical Stage: Phase 1, Phase 2
    • Collaboration: Dry Age-Related Macular Degeneration
      • targeting a single mechanism—the complement pathway—requiring frequent intravitreal injections, either monthly or every other month. By contrast, OCU410 is a multifunctional modifier gene therapy, which targets multiple pathways associated with GA. "The OCU410 Phase 1 and Phase 2 results mark a pivotal moment for Ocugen's modifier gene therapy platform and GA patients worldwide," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "Delivering 60% slower EZ loss in Phase 1 and 46% lesion growth reduction in the Phase 2 preliminary analysis demonstrates the capability of our multi-pathway RORA approach. We look forward to reporting full data from the OCU410 Phase 2 clinical trial later this quarter and initiating Phase 3 in 2026

    🔬 Clinical Development Pipeline (Ocugen Inc.):

    Product Type Development Stage Therapeutic Area Source
    Brimonidine Mono Therapy DRUG Phase PHASE2 Dry Eye ClinicalTrials.gov
    OCU410 GENETIC Phase PHASE1 Geographic Atrophy ClinicalTrials.gov
    Sub-Retinal Administration of OCU400-301 GENETIC Phase PHASE3 Retinitis Pigmentosa ClinicalTrials.gov
    OCU200 DRUG Phase PHASE1 Center Involved Diabetic Macular Edema ClinicalTrials.gov
    OCU410ST DRUG Phase PHASE2 Stargardt Disease ClinicalTrials.gov
    Toca FC DRUG Phase PHASE1 Glioblastoma Multiforme ClinicalTrials.gov
    Toca 511 vector BIOLOGICAL Phase PHASE1 Glioblastoma Multiforme ClinicalTrials.gov
    Toca 511 BIOLOGICAL Phase PHASE1 Glioblastoma Multiforme ClinicalTrials.gov
    Bevacizumab BIOLOGICAL Phase PHASE2 Glioblastoma Multiforme ClinicalTrials.gov
    Temozolomide DRUG Phase PHASE2 Glioblastoma Multiforme ClinicalTrials.gov
    Lomustine DRUG Phase PHASE2 Glioblastoma Multiforme ClinicalTrials.gov
    Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine DRUG Phase PHASE1 Glioblastoma Multiforme ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Dry Eye ClinicalTrials.gov
    Brimonidine 0.075% DRUG Phase PHASE1 Dry Eye ClinicalTrials.gov
    Brimonidine 0.15% DRUG Phase PHASE1 Dry Eye ClinicalTrials.gov
    Toca FC (extended-release formulation of flucytosine) DRUG Phase PHASE1 Bladder Cancer ClinicalTrials.gov
    Placebos DRUG Phase PHASE3 Graft Versus Host Disease ClinicalTrials.gov
    Brimonidine Tartrate DRUG Phase PHASE3 Graft Versus Host Disease ClinicalTrials.gov
    Corticosteroid Eye Drop DRUG Phase PHASE2 Dry Eye ClinicalTrials.gov
    sodium carboxymethylcellulose DRUG Phase PHASE2 Dry Eye ClinicalTrials.gov
    Brimonidine DRUG Phase PHASE2 Dry Eye ClinicalTrials.gov
    BBV152 BIOLOGICAL Preclinical COVID-19 ClinicalTrials.gov
    CUG252 DRUG Phase PHASE1 Systemic Lupus Erythematosus ClinicalTrials.gov
    OCU400 Second Eye Dosing DRUG Phase PHASE1 Retinitis Pigmentosa ClinicalTrials.gov
    OCU400 High Dose DRUG Phase PHASE1 Retinitis Pigmentosa ClinicalTrials.gov
    OCU400 Med Dose DRUG Phase PHASE1 Retinitis Pigmentosa ClinicalTrials.gov
    OCU400 Low Dose DRUG Phase PHASE1 Retinitis Pigmentosa ClinicalTrials.gov
    OCU400 DRUG Preclinical Retinitis Pigmentosa ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Ocugen Inc.
    • Ticker Symbol: OCGN

Search

News categories